Skip to main content
. Author manuscript; available in PMC: 2014 Feb 23.
Published in final edited form as: Am J Cardiol. 2013 Nov 9;113(3):475–479. doi: 10.1016/j.amjcard.2013.10.031

Table 1.

Patient characteristics

Variable All, n = 101 (%) PC Group, n = 47 (%) EC Group, n = 54 (%) p Value
Age, yrs, mean ± SD 61.4 ± 11.5 61.3 ± 9.9 61.6 ± 12.9 0.89
Women 41 (40.6) 18 (38.3) 23 (42.6) 0.66
Time since AF Dx (yrs), median (IQR) 3.82 (1.33–7.38) 4.36 (1.33–7.29) 3.47 (1.27–7.83) 0.96
Duration current AF (mo), median (IQR) 1.86 (0.47–6.03) 1.87 (0.45–5.77) 1.37 (0.47–7.35) 0.82
Dofetilide dose (μg BID)
 125 3 (3.0) 1 (2.1) 2 (3.7) 0.71
 250 45 (44.5) 21 (44.7) 24 (44.4)
 500 53 (52.5) 25 (53.1) 28 (51.9)
QTc, BL (ms), mean ± SD 442 ± 33.4 439.4 ± 40.0 443.8 ± 26.7 0.53
HR, BL (beats/min), mean ± SD 92.9 ± 22.4 95.0 ± 24.2 91.1 ± 21.0 0.39
Previous class IC use 22 (21.8) 14 (29.8) 8 (14.8) 0.07
Previous amiodarone 23 (22.8) 11 (23.4) 12 (22.2) 0.89
Previous AF ablation 10 (9.9) 7 (14.9) 3 (5.6) 0.12
LA size
 Normal 13 (12.9) 6 (12.8) 7 (13.0) 0.35
 Mildly enlarged 20 (19.8) 16 (34.0) 14 (25.9)
 Moderately enlarged 20 (19.8) 11 (23.4) 9 (16.7)
 Severely enlarged 20 (19.8) 6 (12.8) 14 (26.0)
 Not available 18 (17.8) 8 (17.0) 10 (18.5)
Diabetes mellitus 9 (8.9) 6 (12.8) 3 (5.6) 0.24
Hypertension 64 (63.4) 28 (59.6) 36 (66.7) 0.46
Hyperlipidemia 30 (29.7) 15 (31.9) 15 (27.8) 0.65
Heart failure 20 (19.8) 8 (17.0) 8 (17.0) 0.51
Obesity 17 (16.8) 8 (17.0) 8 (17.0) 0.96

Chi-square tests were used to test for differences between categorical variables. t Tests were used to test for differences between normally distributed continuous variables (HR, QTc, and age). Wilcoxon tests were used to test for differences between continuous variables that were not normally distributed (time since AF diagnosis and duration of current AF). LA sizes were defined by American Society of Echocardiography criteria.14

BID = twice daily; BL = baseline; Dx = diagnosis; IQR = interquartile range; LA = left atrium.